SiO2 Medical Products Signs Commercialization Agreement with TheraDep

AUBURN, Ala., Sept. 14, 2017 /PRNewswire/ -- SiO₂ Medical Products, Inc. ("SMP"), a U.S.-based designer, developer, manufacturer, and supplier of pharmaceutical packaging, labware, and consumables products, today announced the signing of an agreement for the manufacture and commercialization of multi-well plates treated with BioDep™ tissue coating technologies developed by TheraDep Technologies, Inc. ("TheraDep"). During the term of the agreement, SMP will be the exclusive supplier of BioDep™ coated cell and tissue culture multi-well plates for general purpose use and non-exclusive partner for such coatings on other labware or consumables.

TheraDep Technologies has developed a rare achievement in medical science, an entirely new therapeutic modality – solving the need for better non-systemic delivery of pure, active biologics or drugs bonded directly to human tissue or to the surfaces of medical devices. BioDep™ coatings are deposited using cold atmospheric plasma-based deposition used in Research and Diagnostics to bind tissue or cells for biological assays and other labware applications. "TheraDep has developed a unique technology to bond active biologic or drug coatings in a single step to any hard surface. The coatings provide significant manufacturing and performance advantages at exceptionally low cost. We are excited to partner with SMP, a company with strong expertise in manufacturing and plasma-based deposition, to accelerate our commercial opportunities," said Patrick Burt, CEO of TheraDep.

The agreement with TheraDep adds another unique plasma coating/treatment technology to SMP's existing portfolio of products. SMP currently manufactures and supplies a broad range of multi-well plates under its PureWARE™ brand in Auburn, Alabama, including PureWARE™ ULB (maximum sample protein/peptide recovery – even at low concentrations), PureWARE™ ULE (minimal extraction of additives or polymeric components into the protein/peptide solution with common organic solvents), and PureWARE™ UC (cleaner contact surface than glass). The multi-well plates are available in a range of formats and are manufactured in a state-of-the-art Class 7 clean room facility. "SMP is excited to add the BioDep™ coatings technology to our existing product portfolio. SMP can leverage our core capabilities in manufacturing and plasma-based deposition to commercialize the BioDep™ coating technology and provide a new offering to the marketplace. Our business engagement with TheraDep will enable us to provide yet another innovative multi-well plate solution to customers in the labware industry," commented Martin Tricarico, Vice President of SMP.

About SiO₂ Medical Products, Inc.:

SiO₂ Medical Products, Inc. (SMP) is a U.S. based, privately-held company founded in 2011. SMP has successfully developed and commercialized a wide range of novel products for use in pharmaceutical packaging, labware, and consumable applications. Using the well-known process of Plasma Enhanced Chemical Vapor Deposition (PECVD), the SiO₂ team has developed proprietary technology to apply thin, transparent coatings or plasma treatments to a broad range of medical devices. The resulting plasma coated medical devices possess outstanding barrier properties, while plasma treated surfaces have ultra-low protein/peptide binding capabilities. SMP is headquartered and has a state-of-the-art, 160,000 sq. ft. manufacturing and R&D facility in Auburn, Alabama; with sales, marketing, legal, and project management capabilities based out of offices near Philadelphia, Pennsylvania. For more information, visit www.sio2med.com.

About TheraDep Technologies, Inc.:

TheraDep Technologies, Inc., founded in 2015, is a Palo Alto, California based, privately held company with research and development facilities in Ireland and the U.S. TheraDep has developed BioDep™, a novel, patented process to covalently bond biologics or drugs onto any device or labware material, or to human tissue for targeted, non-systemic delivery. The coatings are pure and without the presence of any linker agents, carriers or synthetic polymers and without the need for incubation. The process uses cold atmospheric plasma (CAP) to deposit thin, uniform coatings in a single, low cost and high throughput activation/deposition step. For more information, visit www.theradep.com.    

For more information contact Jaimin B. Shah ([email protected]) and/or Patrick Burt ([email protected]).

SOURCE SiO2 Medical Products, Inc.

Related Links

http://www.sio2med.com